International standards of cost-effectiveness evaluation;Internationale standards der kosten-nutzen-bewertung

Gesundheitsokonomie und Qualitatsmanagement

Volumn 11, Issue 6, 2006, Pages 368-373

  Zentner, Annette ^a   Busse, R ^a  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Drug evaluation; Methods; Pharmaceutical economics

Indexed keywords

COST EFFECTIVENESS ANALYSIS; HEALTH CARE UTILIZATION; HEALTH CENTER; HEALTH SERVICE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 33847411450     PISSN: 14322625     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-927192     Document Type: Review

References (22)

1. Zentner A, Velasco-Garrido M, Busse R. Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. Eine internationale Bestandaufnahme. GMS Health Technol Assess 2005; 1: Doc09 (20051115). http://www.egms.de/pdf/ journals/hta/2005-1/hta000009.pdf
2. Commonwealth Department of Health and Ageing. Guidelines for the pharmaceutical Industry on Preparations of Submissions to the Pharmaceutical Benefits Advisory Committee. 2002. http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/health-pbs-general-pubs-guidelines-index.htm/ $FILE/guidelines.pdf
3. nd edition. 1997. http://www.cadth.ca/media/pdf/peg_e.pdf
4. Glennie JL, Torrance GW, Baladi JF et al. The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. PharmacoEconomics 1999; 15 (5): 459-468
5. Hauptverband der österreichischen Sozialversicherungsträ ger. Geschäftsordnung der Heilmittelevaluierungskommission gemäß §9 Abs. 2 der Verfahrensordnung zur Herausgabe des Erstattungskodex. 2004. http://www.avsv.at
6. Johannesson M, Jonsson B, Karlsson G. Outcome measurement in economic evaluation. Health Economics 1996; 5 (4): 279-296
7. Gold MR, Siegel JE, Russell LB et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
8. National Institute for Clinical Excellence. Guidance for Manufacturers and Sponsors. 2004. http://www.nice.org.uk/pdf/TAP_Methods.pdf
9. Pharmaceutical Management Agency (PHARMAC). A Prescription for pharmacoecomic Analysis Version 1.1. 2004. http://www.pharmac.govt.nz/pdf/pfpa. pdf
10. Drummond MF, O'Brien B, Stoddart GL et al. Methods for the economic Evaluation of Health Care Programmes. New York: Oxford University Press, 1997
11. Ministry of Social Affairs and Health. Guidelines for preparation of an account of health-economic aspects (inoffizielle englische Übersetzung). Helsinki: Ministry of Social Affairs and Health, 1999
12. Norwegian Medicines Agency (Statens Legemiddelverk). Norwegian Guidelines for pharmacoeconomic Analysis in Connection with Applications for Reimbursement 2005. http://www.legemiddelverket.no/InterPage_20669.aspx
13. College voor zorgverzekeringen. Dutch Guidelines for pharmacoeconomic Research. 1999. http://www.ispor.org/PEguidelines/source/ PE_guidelines_english_Netherlands.pdf
14. Pharmaceutical Benefits Board (Läkemedelsförmånsä mnden). General Guidelines for economic Evaluations from the Pharmaceutical Benefits Board. 2003. http://www.lfn.se/documents/In%20English/ENG_Ifnar2003- eng.pdf
15. Luce BR, Manning WG, Seigel KE et al. Estimating costs in cost-effectiveness analysis. In: Gold MR, Seigel JE, Russell LB, Weinstein MC (Hrsg). Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 176-213
16. Brouwer W, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life? A response to the recommendations of the Washington Panel. Health Economics 1997; 6 (3): 253-259
17. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Medical Care 1993; 31 (5): 403-418
18. Schöffski O, Schulenburg JM. Gesundheitsökonomische Evaluation. Studienausgabe. Berlin, Heidelberg, New York: Springer, 2001
19. Brouwer W. A fair approach to discounting future effects: Taking a social perspective. Journal of Health Services Research and Policy 2000; 5: 114-118
20. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC (Hrsg). Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214-246
21. Halpern MT. Health and economic outcomes modelling practices: a suggested framework. Value in Health 1998; 1: 131-147
22. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic costeffectiveness models. Pharmacoeconomics 2000; 17: 461-477